Research on hormone therapy and its effects. Covers menopause symptom relief, bronchiectasis risk, dementia links, and Alzheimer's risk.
Researchers have discovered a promising new treatment that preserves bone mass in both female and male mice without affecting reproductive organs. Estren, a class of compounds called ANGELS, appears to trigger bone-building activities without the side effects associated with sex hormone therapy.
A new study found that synthetic hormone estren can build bone in animals without affecting reproductive organs. The researchers tested estren, estrogen, and testosterone in mice with and without sex organs, showing estren's potential to provide a safe form of hormone replacement therapy.
A new study published in the journal Science suggests that estren, a synthetic compound, can build bone and improve bone density and strength without affecting reproductive organs. The findings may indicate a potential alternative to standard hormone replacement therapy for treating osteoporosis in both men and women.
A study by Professor Lesley Fallowfield found that psychosocial discussions are often overlooked in cancer treatment consultations. Training can help doctors and nurses discuss personal and sexual issues comfortably and sensitively, improving patient outcomes.
The American College of Physicians' Task Force concludes that combined estrogen and progestin therapy has more likely to cause harm than benefit for most women. The evidence is insufficient to recommend hormone therapy alone or together for preventing chronic conditions in postmenopausal women with hysterectomies.
A population-based study of 2,786 diabetic and non-diabetic postmenopausal women found that HRT had a positive effect on blood levels of fats and glucose. Diabetic women on HRT had significantly lower fasting levels of total cholesterol and higher levels of beneficial high-density lipoprotein.
The study found that hormone replacement therapy (HRT) increases the risk of breast cancer, pulmonary embolism, and stroke in women, while reducing the risk of colorectal cancer and hip fractures. HRT may also increase the risk of cardiovascular disease among older women.
A recent study by OHSU suggests that hormone replacement therapy (HRT) can lead to improved breast cancer detection and survival rates. The research found that HRT users had a 100% survival rate after six years, compared to an 87% survival rate for non-users.
The InnoLet system features a dosing dial and reversible dose mechanism, making it easier for patients to administer accurate doses. Clinical studies show that 95% of participants rated the device as 'very easy' or 'easy' to use.
A new study found that flu vaccines can benefit healthy working adults aged 18-50 by avoiding lost work time and treatment costs. Hormone replacement therapy does not prevent or reduce the rate of developing heart disease, contrary to earlier studies.
Researchers are conducting clinical trials to restore sexual desire in menopausal women using an investigational skin patch. Approximately 43% of women experience some form of difficulty in their sexual function, significantly higher than men.
A study of 44,241 women found that postmenopausal estrogen-only therapy increases the risk of ovarian cancer by 60%, with a greater risk for those using therapy for 10 or more years. The relative risk was highest for women who used estrogen for 20 or more years.
A new study suggests that growth hormone therapy can significantly enhance human thymic function and increase the production of new T cells in HIV-infected patients. This could potentially help preserve and restore their immune systems. However, more research is needed to confirm these findings and ensure the benefits outweigh the risks.
Researchers found that adding hormone-suppression therapy to radiotherapy for advanced prostate cancer significantly improved five-year disease-free survival rates. The study involved 415 patients, with those receiving combined therapy showing a substantial increase in overall survival rates.
The Women's Health Initiative has stopped its trial on estrogen-progestin combination Prempro due to significant increased risk of breast cancer and cardiovascular events. Women taking this medication will continue with regular contacts, exams, and mammograms.
A new needle-free device called J-Tip has been successfully used to administer hormones to women undergoing IVF treatment. The device enabled the retrieval of eggs from 16 out of 20 women, resulting in four pregnancies. Patient acceptance was high, with diaries indicating a clear preference for the needle-free approach.
A long-term study of hormone therapy in postmenopausal women with heart disease found no reduction in heart attack risk and increased blood clot risk. The therapy also showed a higher risk of gallbladder disease requiring surgery.
A study of 50 healthy postmenopausal women found that a specific exercise program reduced the risk of vertebral fractures and retained benefits for eight years after completion. The exercise group had lower bone density loss and better back strength than the control group.
Research by Wake Forest University professor suggests that hormone replacement therapy can help prevent heart vessel disease when started at the right time. Studies on postmenopausal monkeys and younger women have found a strong link between estrogen therapy and reduced fatty build-up in the heart's arteries.
A study found that customizing HRT education materials can personalize risk versus benefit for individual women, increasing their confidence in decision-making. The intervention helped women accurately perceive their breast cancer risk and weigh its benefits against HRT.
A new study found that estrogen combined with calcium and vitamin D supplements improved jaw mass and density in postmenopausal women, reducing the risk of tooth loss. The study also showed that estrogen had a significant impact on bone mineral density in other parts of the skeleton.
A new study found that anastrozole improved disease-free survival and was better tolerated than tamoxifen. Anastrozole may be a viable alternative to tamoxifen for adjuvant treatment of early breast cancer in postmenopausal women.
Researchers at the University at Buffalo found that estrogen can suppress production of pro-inflammatory components, reducing atherosclerosis risk. Estrogen may help explain why women have lower heart disease risk until menopause.
A new study found that anastrozole improved disease-free survival and was better tolerated than tamoxifen, a current standard treatment. The ATAC trial also showed no additional benefit from combining both drugs.
A study by E. Todd Schroeder and colleagues found that androgen therapy increased muscle mass, strength, and power in older men, improving their ability to perform daily activities. The findings suggest that supplemental androgen therapy might benefit older men prone to losing muscle mass due to sarcopenia.
Researchers developed a transdermal HRT patch that increased androgen levels, leading to higher libido and greater sexual satisfaction in postmenopausal women. The study suggests a potential new treatment approach for female sexual dysfunction, building on preliminary research showing testosterone supplements can enhance sex drive.
Researchers found that estradiol levels changed significantly during exercise for women using transdermal estrogen patches, but returned to normal within thirty minutes. In contrast, other hormones showed no significant changes during exercise with oral or transdermal administration.
Researchers at Emory University Health Sciences Center are launching a three-year pilot study to evaluate the effectiveness of progesterone in treating traumatic brain injury. The study aims to determine whether giving progesterone to victims of moderate to severe traumatic brain injury can save lives and preserve mental function.
A new study found that hormone replacement therapy, particularly estrogen alone, may increase the risk of epithelial ovarian cancer in postmenopausal women with an intact uterus. Women who used sequential progestins with estrogens had a higher risk of developing ovarian cancer compared to those who never used HRT.
Researchers found that women with a common mutation in the estrogen receptor alpha gene had dramatic increases in high-density lipoprotein (HDL), or the 'good' cholesterol. This discovery suggests that genetic testing may help doctors make better decisions about hormone replacement therapy for preventing heart disease.
A new study by Eckehard Liske, PhD, confirms the safety and efficacy of RemiFemin in relieving menopausal symptoms. The research shows that standardized herbal supplement works without affecting hormone levels, reducing hot flashes, mood swings, night sweats, and sleeplessness.
A long-term follow-up study of over 800 postmenopausal women found that stopping hormone replacement therapy resumes bone loss at a rate similar to those who never took the drugs. The study showed that while bone mass increased in the first 36 months after starting hormone replacement therapy, there was little gain after that.
Recent improvements in hormonal therapy and understanding of molecular mechanisms indicate that hormone therapy is more effective than chemotherapy in treating early breast cancer. The use of GnRH antagonists and aromatase inhibitors holds promise for treating younger women and post-menopausal patients, respectively.
A study found that hormone therapy slows atherosclerosis progression in monkeys with healthy blood vessels. Estrogen was most effective when given at an early stage, suggesting it may be less beneficial for women with advanced arterial disease.
A recent study found that Prozac significantly reduced hot flashes in women with breast cancer, providing a viable treatment option. The medication was compared to placebo and showed a 50% decrease in hot flash frequency and severity.
A Mayo Clinic study finds an association between estrogen status and reduced coronary calcium and plaque area, suggesting a potential benefit against heart disease. Estrogen may modulate the calcium content of atherosclerotic plaques, slowing progression of atherosclerosis in women.
A pilot study suggests that continuous administration of GLP-1 can improve insulin sensitivity, b-cell function, and reduce blood glucose levels in patients with type 2 diabetes. The treatment also resulted in weight loss and reduced appetite, with no reported side effects.
A study by Massachusetts General Hospital found that hormone therapy for prostate cancer can lead to significant weight gain, increased body fat, and decreased muscle mass. Researchers suggest modifying diet and exercise may help mitigate these effects, but better drugs are needed.
A study published in the American Journal of Clinical Nutrition found that moderate alcohol consumption can lower cardiovascular risk factors in postmenopausal women. The researchers observed significant improvements in lipid profiles, with a greater benefit for those starting with higher levels of LDL-cholesterol and triacylglycerols.
Research suggests that hormone replacement therapy (HRT) may help prevent chronic wounds, such as pressure ulcers and venous leg ulcers, in elderly female patients. Studies have shown a 35% lower risk of developing these wounds among HRT recipients.
A recent study published in The Lancet found that hormone replacement therapy (HRT) may help prevent venous leg ulcers and pressure sores in elderly women. Researchers analyzed data from over 45,000 patients and discovered a 35% lower risk of developing these chronic wounds among HRT users.
Researchers found that raloxifene did not further prevent the growth of breast tumors previously exposed to more than 5 years of tamoxifen. Raloxifene also failed to block the growth of endometrial tumors caused by low-dose estrogen, suggesting it may increase endometrial cancer risk.
Researchers found that raloxifene reduced the risk of cardiovascular events by 40% in postmenopausal women with osteoporosis who were also at high risk for cardiovascular disease. A subset of 1,035 women showed a significant reduction in cardiovascular events compared to placebo.
Researchers found that raloxifene did not prevent growth of breast tumors previously exposed to tamoxifen, while being less effective in blocking endometrial tumor growth. The study suggests that raloxifene may not further reduce the risk for breast cancer recurrence after five years of tamoxifen therapy.
A recent study by Mayo Clinic researchers has confirmed that long-term use of venlafaxine provides women with breast cancer significant relief from hot flashes, with a 60% reduction in frequency over eight weeks. The antidepressant is considered a safe and effective non-hormonal alternative to estrogen for treating hot flashes.
A recent study found that depression treatments are less effective among certain populations, including elderly women and individuals with low education levels. These populations tend to have higher rates of non-response to treatment, suggesting the need for more intensive specialty mental health care.
Researchers found that growth hormone therapy stimulated immunity-promoting cells in bone marrow and other organs of aging rats, increasing red and white blood cell production by up to three times. This approach could lead to increased reserve capacity for immune cells in the elderly.
A Stanford study shows that hormone therapy can improve mental health and reduce depression in women experiencing hot flashes, but may have negative effects on those without symptoms. The research suggests that women should discuss their individual risks and benefits with their doctor before making a decision.
Researchers at Lehigh University have discovered a possible cause-and-effect relationship between DHEA and the workings of the body's central nervous system. The study found that DHEA influences gene function through interaction with androgen receptors, potentially contributing to improved neuron survival and cognitive function.
A collaborative study found that lifetime exposure to hormone replacement therapy (HRT) may be associated with better maintenance of cognitive function in older women free of dementia. The study included over 2,000 women aged 65 and older, who were followed for three years to assess changes in cognition and depression status.
A randomized controlled trial found that unopposed estrogen therapy reduced atherosclerosis progression by .0017 millimeters per year in postmenopausal women. The study also showed that cholesterol-lowering drugs had a similar effect when combined with estrogen, suggesting potential benefits for cardiovascular health in women at risk.
A study published in 2001 found that patients with autism who received secretin showed no statistically significant improvements in core symptoms compared to those who received a placebo. The researchers tested porcine secretin and found no improvement in secondary measures of autism either.
A new study published in The Lancet reveals that pegvisomant normalized IGF-I concentrations in 97% of patients with acromegaly after 12 months of treatment. Patients experienced improved symptoms and a better quality of life, highlighting the potential benefits of this innovative drug.
A new study found that Actonel 35mg taken once a week was equally effective to 5mg daily in improving bone density in postmenopausal women. The treatment also showed a comparable adverse event profile. This alternative dosing regimen may be beneficial for some patients and physicians.
A two-year study of postmenopausal monkeys found tibolone improved bone mineral density while reducing cardiovascular risks compared to estrogen-based treatments. However, it may offer advantages in breast and uterine safety over other options.
The study, published in the New England Journal of Medicine, found that estrogen replacement therapy for secondary stroke prevention was not beneficial. The Yale team also discovered a borderline higher risk of fatal stroke among women taking estradiol.
A new randomized, controlled clinical trial found no significant difference in the incidence of stroke or death among postmenopausal women who received estrogen therapy. The study suggests that estrogen should not be prescribed for preventing a second stroke or death in these patients.
The rate of prostate cancer diagnosis has increased significantly, with only 3-5% of newly diagnosed patients having advanced disease. However, the impact of this shift on mortality rates is uncertain, as PSA screening can lead to over-treatment and unnecessary aggressive treatment.
A new computer tool forecasts individualized treatment outcomes and risk assessments for patients with breast cancer. The program provides easy-to-read reviews of different treatment options, helping patients make informed decisions about their care.
Research suggests that estrogen replacement drugs can modify vein function in ways that increase the risk of venous thrombosis. Studies using adult female pigs found that hormone replacement therapies containing estradiol and SERMs altered cellular processes in veins, leading to changes in diameter, relaxation, and coagulation.